Published 2026-07-22 · Seno.Bio Platform Team
China's 2026 round of drug and medical device regulatory reform meaningfully shortens several review and approval steps that directly affect how long it takes an innovative product to move from nonclinical evaluation to market. For companies planning GLP and CDMO timelines, the changes are worth building into project plans now.
| Reform item | Previous | New |
|---|---|---|
| Clinical trial review & approval | 60 working days | 30 working days |
| Priority inspection for innovative devices | Standard queue | Received-and-inspected on submission |
| Rare-disease device clinical trials | Standard requirements | Clinical trial exemption pathway available |
| Rare-disease device registration testing | 3 batches | 1 batch |
Halving clinical trial review time and moving innovative devices to received-and-inspected status compresses the window between finishing nonclinical evaluation and getting into clinical trials — which is exactly the handoff point where a well-run GLP process matters most. For rare-disease device programs, the exemption pathway and reduced batch-testing requirement can meaningfully shorten the path to registration. Combined, these changes lower the cost and time pressure that CDMO and GLP planning needs to absorb.
Source: State Council General Office, "Opinions on Comprehensively Deepening the Reform of Drug and Medical Device Regulation" (2026); People's Daily coverage of clinical trial review timeline reductions. Figures current as of publication and subject to implementation guidance.